What is it about?
From a web-based survey, we collected data from French and Spanish people with multiple sclerosis (n=641). We found similar percentages of cannabis-based products users among both sub-populations (~20%). Such users were more likely to suffer from greater disability and pain than non-users. Herb/resin was the most commonly used product.
Featured Image
Photo by Christina Winter on Unsplash
Why is it important?
Our findings show that multiple sclerosis patients the most in need of relief are likely to use cannabis-based products to alleviate their symptoms, especially herb/resin, regardless of the local legislation.
Perspectives
I hope those results will participate in making the voice of patients heard so that access to safe cannabis-based products will be eased.
Tangui Barré
Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, France
Read the Original
This page is a summary of: Symptom severity is a major determinant of cannabis‐based products use among people with multiple sclerosis, Journal of Clinical Nursing, March 2023, Wiley,
DOI: 10.1111/jocn.16674.
You can read the full text:
Contributors
The following have contributed to this page
